Cited by 151Cannabis and Cannabinoid ResearchNigella sativa pharmacological applicationsEpilepsy research and treatment

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Therapeutic potential of cannabis-related drugs

Alexander, Stephen P.H.·2016·Progress in Neuro-Psychopharmacology and Biological Psychiatry

DOI 10.1016/j.pnpbp.2015.07.001

Open this paper in CoChat — free account

Abstract

In this review, I will consider the dual nature of Cannabis and cannabinoids. The duality arises from the potential and actuality of cannabinoids in the laboratory and clinic and the 'abuse' of Cannabis outside the clinic. The therapeutic areas currently best associated with exploitation of Cannabis-related medicines include pain, epilepsy, feeding disorders, multiple sclerosis and glaucoma. As with every other medicinal drug of course, the 'trick' will be to maximise the benefit and minimise the cost. After millennia of proximity and exploitation of the Cannabis plant, we are still playing catch up with an understanding of its potential influence for medicinal benefit.

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2015.07.001

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,389
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Marzo, V. D., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,666
Self-citation
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,511
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J. H., Berger, J. P., Chatterjee, K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,022
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavón, F. J., Serrano, A., Selley, D. E., Parsons, L. H., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.129 · Cited by 954
Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder, C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., & Mitchell, R. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10492-6 · Cited by 900
Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & CEBALLOS, M. L. D. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4540-04.2005 · Cited by 801
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol
Kirkham, T. C., Williams, C. M., Fezza, F., & Marzo, V. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704767 · Cited by 788
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi, M. L., Barth, F., Millan, J., Derocq, J., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 716
Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.005 · Cited by 710
Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation
Galve‐Roperh, I., Sánchez, C., Cortés, M. L., del Pulgar, T. G., Izquierdo, M., & Guzmán, M. (2000) · Nature Medicine · doi:10.1038/73171 · Cited by 686
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents
Overton, H. A., Babbs, A. J., Doel, S. M., Fyfe, M. C. T., Gardner, L. S., Griffin, G., Jackson, H. C., Procter, M. J., Rasamison, C. M., Tang‐Christensen, M., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.004 · Cited by 670
CB2: a cannabinoid receptor with an identity crisis
Atwood, B. K., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00729.x · Cited by 659
History of Cannabis and Its Preparations in Saga, Science, and Sobriquet
Russo, E. B. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790144 · Cited by 630
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors
Arnone, M., Maruani, J., Chaperon, F., Thiébot, M.-H., Poncelet, M., Soubrié, P., & Fur, G. L. (1997) · Psychopharmacology · doi:10.1007/s002130050326 · Cited by 593
The draft genome and transcriptome of Cannabis sativa.
van Bakel, H., Stout, J. M., Cote, A. G., Tallon, C. M., Sharpe, A. G., Hughes, T. R., & Page, J. E. (2011) · Genome Biology · doi:10.1186/gb-2011-12-10-r102 · Cited by 575
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders [RETIRED]
Koppel, B. S., Brust, J. C. M., Fife, T. D., Bronstein, J. M., Youssof, S., Gronseth, G., & Gloss, D. S. (2014) · Neurology · doi:10.1212/wnl.0000000000000363 · Cited by 554
Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
McPartland, J. M., Duncan, M., Marzo, V. D., & Pertwee, R. G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 552
Cannabinoids control spasticity and tremor in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J., Brown, P., Pertwee, R., Huffman, J. W., & Layward, L. (2000) · Nature · doi:10.1038/35003583 · Cited by 546
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
O’Sullivan, S. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707423 · Cited by 509
Health aspects of cannabis
Hollister, L. E. (1987) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(87)90030-4 · Cited by 500
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis: Sativex for refractory spasticity in MS
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
Structure−Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists
Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S. R., McCallion, D. S. E., Pertwee, R. G., & Makriyannis, A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980363y · Cited by 449
Cannabinoid CB 2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain
Guindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423
Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability
Iannotti, F. A., Hill, C. L., Leo, A., Alhusaini, A. M., Soubrane, C., Mazzarella, E., Russo, E., Whalley, B. J., Marzo, V. D., & Stephens, G. J. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5000524 · Cited by 414
Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630
Ross, R. A., Brockie, H. C., Stevenson, L., Murphy, V. L., Templeton, F., Makriyannis, A., & Pertwee, R. G. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702351 · Cited by 411
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
Martin, B. R., Compton, D. M., Thomas, B. F., Prescott, W. R., Little, P., Razdan, R. K., Johnson, M. R., Melvin, L. S., Mechoulam, R., & Ward Susan, J. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90349-7 · Cited by 410
Systematic review of tools to measure outcomes for young children with autism spectrum disorder
McConachie, H., Parr, J. R., Glod, M., Hanratty, J., Livingstone, N., Oono, I. P., Robalino, S., Baird, G., Beresford, B., Charman, T., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19410 · Cited by 403
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., et al. (2009) · Brain · doi:10.1093/brain/awp239 · Cited by 382
Synthesis and Characterization of Potent and Selective Agonists of the Neuronal Cannabinoid Receptor (CB1)
Hillard, C. J., Manna, S., Greenberg, M. J., DiCamelli, R. F., Ross, R. A., Stevenson, L., Murphy, V. L., Pertwee, R. G., & Campbell, W. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38289-8 · Cited by 378
An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee
Huggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
Peroxisome Proliferator-Activated Receptors
Schiffrin, E. L., Amiri, F., Benkirane, K., Iglarz, M., & Diep, Q. N. (2003) · Hypertension · doi:10.1161/01.hyp.0000084370.74777.b6 · Cited by 370
A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals
Wei, B. Q., Mikkelsen, T. S., McKinney, M. K., Lander, E. S., & Cravatt, B. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606646200 · Cited by 368
A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
Guzmán, M., Duarte, M. C. L. F., Blázquez, C., Ravina, J., Rosa, M. C., Galve‐Roperh, I., Sánchez, C., Velasco, G., & González‐Feria, L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603236 · Cited by 366
Tissue-specific Functions in the Fatty Acid-binding Protein Family
Storch, J., & THUMSER, A. E. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.135210 · Cited by 363
Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes
Durinck, S., Stawiski, E. W., Pavía-Jiménez, A., Modrusan, Z. D., Kapur, P., Jaiswal, B. S., Zhang, N., Tcheuyap, V. T., Nguyen, T. T., Pahuja, K. B., et al. (2014) · Nature Genetics · doi:10.1038/ng.3146 · Cited by 358
Localization of Diacylglycerol Lipase-α around Postsynaptic Spine Suggests Close Proximity between Production Site of an Endocannabinoid, 2-Arachidonoyl-glycerol, and Presynaptic Cannabinoid CB1 Receptor
Yoshida, T., Fukaya, M., Uchigashima, M., Miura, E., Kamiya, H., Kano, M., & Watanabe, M. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0054-06.2006 · Cited by 334
International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands
Davenport, A. P., Alexander, S. P. H., Sharman, J. L., Pawson, A. J., Benson, H. E., Monaghan, A. E., Liew, W. C., Mpamhanga, C. P., Bonner, T. I., Neubig, R. R., et al. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007179 · Cited by 329
Self-citation
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
PETROCELLIS, L. D., Orlando, P., Moriello, A. S., Aviello, G., Stott, C. G., Izzo, A. A., & Marzo, V. D. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02338.x · Cited by 326
Identification of intracellular carriers for the endocannabinoid anandamide
Kaczocha, M., Glaser, S. T., & Deutsch, D. G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901515106 · Cited by 326
Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
Elmes, M. W., Kaczocha, M., Berger, W. T., Leung, K., Ralph, B. P., Wang, L., Sweeney, J., Miyauchi, J. T., Tsirka, S. E., Ojima, I., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.618447 · Cited by 315
Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonist
Rinaldi, M. L., Barth, F., Héaulme, M., Alonso, R., Shire, D. J., Congy, C., Soubrié, P., Brelière, J.-C., & Fur, G. L. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00174-5 · Cited by 307
The enigmatic pharmacology of GPR55
Ross, R. A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.004 · Cited by 300
2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans
Hansen, K. B., ROSENKILDE, M. M., Knop, F. K., Wellner, N., Diep, T. A., Rehfeld, J. F., Andersen, U. B., Holst, J. J., & Hansen, H. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0647 · Cited by 298
The GPR55 ligand L‐α‐lysophosphatidylinositol promotes RhoA‐dependent Ca 2+ signaling and NFAT activation
Henstridge, C. M., Balenga, N. A. B., Ford, L., Ross, R. A., Waldhoer, M., & Irving, A. J. (2008) · The FASEB Journal · doi:10.1096/fj.08-108670 · Cited by 294
3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor
Huffman, J. W., Liddle, J., Yu, S., Aung, M. M., Abood, M. E., Wiley, J. L., & Martin, B. R. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00219-9 · Cited by 290
FAAH genetic variation enhances fronto-amygdala function in mouse and human
Dincheva, I., Drysdale, A. T., Hartley, C. A., Johnson, D. C., Jing, D., King, E. C., Ra, S., Gray, J. M., Yang, R., DeGruccio, A. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7395 · Cited by 289
Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands
Kapur, A., Zhao, P., Sharir, H., Bai, Y., Caron, M. G., Barak, L. S., & Abood, M. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.050187 · Cited by 286
Cyclohexylcarbamic Acid 3‘- or 4‘-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure−Activity Relationships, and Molecular Modeling Studies
Mor, M., Rivara, S., Lodola, A., Plazzi, P. V., Tarzia, G., Duranti, A., Tontini, A., Piersanti, G., Kathuria, S., & Piomelli, D. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031140x · Cited by 277
Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18
Kohno, M., Hasegawa, H., Inoue, A., Muraoka, M., Miyazaki, T., Oka, K., & Yasukawa, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.175 · Cited by 272
A systematic review of the antipsychotic properties of cannabidiol in humans
Iseger, T. A., & Bossong, M. G. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.033 · Cited by 261
Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model.
Howlett, A. C., Johnson, M. R., Melvin, L. S., & Milne, G. M. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13196-9 · Cited by 253
Δ9‐Tetrahydrocannabinol andN‐arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC‐1B cells
McHugh, D., Page, J., Dunn, E., & Bradshaw, H. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01497.x · Cited by 251
Cannabinoids for epilepsy
Gloss, D. S., & Vickrey, B. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009270.pub3 · Cited by 244
Health aspects of cannabis.
Hollister, L. E. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06862-0 · Cited by 242
Cannabidiol as potential anticancer drug
Massi, P., Solinas, M., Cinquina, V., & Parolaro, D. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04298.x · Cited by 241
Role of Fatty Acid Binding Proteins and Long Chain Fatty Acids in Modulating Nuclear Receptors and Gene Transcription
Schroeder, F., Petrescu, A. D., Huang, H., Atshaves, B. P., McIntosh, A. L., Martin, G. G., Hostetler, H. A., Vespa, A., Landrock, D., Landrock, K. K., et al. (2007) · Lipids · doi:10.1007/s11745-007-3111-z · Cited by 239
LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation
Felder, C. C., Joyce, K. E., Briley, E. M., Glass, M., Mackie, K., Fahey, K. J., Cullinan, G. J., Hunden, D. C., Johnson, D. W., Chaney, M. O., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37189-7 · Cited by 238
Loss of cannabinoid receptors in the substantia nigra in huntington's disease
Glass, M., Faull, R. L. M., & Dragunow, M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90352-g · Cited by 235
Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice
Hao, S., Avraham, Y., Mechoulam, R., & Berry, E. M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00059-5 · Cited by 229
Systematic Review and Meta-analysis of Cannabis Treatment for Chronic Pain
Martín-Sánchez, E., Furukawa, T. A., Taylor, J., & Martín, J. L. R. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00703.x · Cited by 227
Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice
Parmentier‐Batteur, S., Jin, K., Mao, X. O., Xie, L., & Greenberg, D. A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09771.2002 · Cited by 226
CB 1 cannabinoid receptor‐mediated modulation of food intake in mice
Wiley, J. L., Burston, J. J., Leggett, D. C., Alekseeva, O. O., Razdan, R. K., Mahadevan, A., & Martin, B. R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706157 · Cited by 221
Therapeutic potential of monoacylglycerol lipase inhibitors
Mulvihill, M. M., & Nomura, D. K. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.10.025 · Cited by 205
Induction of Psychosis byΔ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing
Bhattacharyya, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.161 · Cited by 203
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain
Roques, B. P., Fournié‐Zaluski, M., & Wurm, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3673 · Cited by 198
2-Arachidonoyl-sn-glycero-3-phosphoinositol: A Possible Natural Ligand for GPR55
Oka, S., Toshida, T., Maruyama, K., Nakajima, K., Yamashita, A., & Sugiura, T. (2008) · The Journal of Biochemistry · doi:10.1093/jb/mvn136 · Cited by 197
Properties of rat liver N-acylethanolamine amidohydrolase.
Schmid, P. C., Zuzarte‐Augustin, M. L., & Schmid, H. H. O. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38695-7 · Cited by 196
Endocannabinoids in the retina: From marijuana to neuroprotection
Yazulla, S. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.07.002 · Cited by 188
Time-dependent vascular actions of cannabidiol in the rat aorta
O’Sullivan, S. E., Sun, Y., Bennett, A. J., Randall, M. D., & Kendall, D. A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.010 · Cited by 185
Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus
Richfield, E. K., & Herkenham, M. A. (1994) · Annals of Neurology · doi:10.1002/ana.410360406 · Cited by 177
Endogenous Fatty Acid Ethanolamides Suppress Nicotine-Induced Activation of Mesolimbic Dopamine Neurons through Nuclear Receptors
Melis, M., Pillolla, G., Luchicchi, A., Muntoni, A. L., Yaşar, S., Goldberg, S. R., & Pistis, M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3221-08.2008 · Cited by 173
Transport of endocannabinoids across the plasma membrane and within the cell
Fowler, C. J. (2013) · FEBS Journal · doi:10.1111/febs.12212 · Cited by 168
Novel time-dependent vascular actions of Δ9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma
O’Sullivan, S. E., Tarling, E. J., Bennett, A. J., Kendall, D. A., & Randall, M. D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.121 · Cited by 159
Activation of GPR 18 by cannabinoid compounds: a tale of biased agonism
Console‐Bram, L., Brailoiu, E., Brailoiu, G. C., Sharir, H., & Abood, M. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12746 · Cited by 157
Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation
Bluett, R. J., Gamble-George, J. C., Hermanson, D. J., Hartley, N. D., Marnett, L. J., & Patel, S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.53 · Cited by 157
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea‐induced behaviour in rats by enhancing 5‐HT1A receptor activation
Bolognini, D., Rock, E., Cluny, N., Cascio, M., Limebeer, C., Duncan, M., Stott, C., Javid, F., Parker, L., & Pertwee, R. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12043 · Cited by 151
The synthetic cannabinoid WIN55212‐2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies
Porcella, A., Maxia, C., Gessa, G. L., & Pani, L. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2000.01401.x · Cited by 150
Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain
Jhaveri, M. D., Richardson, D. S., & Chapman, V. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707433 · Cited by 147
Medical marijuana for cancer
Kramer, J. L. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21260 · Cited by 138
The complications of promiscuity: endocannabinoid action and metabolism
Alexander, S. P. H., & Kendall, D. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707456 · Cited by 136
Self-citation
Fine-Scale Survey of X Chromosome Copy Number Variants and Indels Underlying Intellectual Disability
Whibley, A. C., Plagnol, V., Tarpey, P. S., Abidi, F., Fullston, T., Choma, M. K., Boucher, C. A., Shepherd, L., Willatt, L. R., Parkin, G., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.06.017 · Cited by 135
Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide11Abbreviations: AEA, anandamide, arachidonyl ethanolamide; PEA, palmitoylethanolamide, N-(2-hydroxyethyl) hexadecamide; FAAH, fatty acid amide hydrolase; CB, cannabinoid; PMSF, phenylmethylsulfonyl fluoride; MAFP, methyl arachidonyl fluorophosphonate; methAEA, arachidonyl-1′-hydroxy-2′-propylamide; and NSAIDs, nonsteroidal anti-inflammatory drugs.
Fowler, C. J., Jonsson, K., & Tiger, G. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00712-2 · Cited by 129
Activation and Binding of Peroxisome Proliferator-Activated Receptor γ by Synthetic Cannabinoid Ajulemic Acid
Liu, J., Li, H., Burstein, S. H., Zurier, R. B., & Chen, J. D. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.983 · Cited by 129
Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases
Urquhart, P., Nicolaou, A., & Woodward, D. F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.015 · Cited by 125
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain
Jhaveri, M. D., Richardson, D. S., Robinson, I., Garle, M. J., Patel, A., Sun, Y., Sagar, D. R., Bennett, A. J., Alexander, S. P. H., Kendall, D. A., et al. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.04.018 · Cited by 122
Self-citation
Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo
Laere, K. V., Casteels, C., Lunskens, S., Goffin, K. E., Grachev, I. D., Bormans, G. M., & Vandenberghe, W. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.009 · Cited by 120
Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma
Vara‐Ciruelos, D., Morell, C., Rodríguez‐Henche, N., & Díaz‐Laviada, I. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.141 · Cited by 109
The contribution of cyclooxygenase‐2 to endocannabinoid metabolism and action
Fowler, C. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707379 · Cited by 104
Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson’s disease
García, M. C., Cinquina, V., Palomo‐Garo, C., Rábano, A., & Fernández‐Ruíz, J. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.12.003 · Cited by 103
Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages
Sun, Y., Tsuboi, K., Zhao, L., Okamoto, Y., Lambert, D. M., & Ueda, N. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2005.08.010 · Cited by 103
The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein
Porcella, A., Maxia, C., Gessa, G. L., & Pani, L. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.01027.x · Cited by 102
Lipid Droplets Are Novel Sites of N-Acylethanolamine Inactivation by Fatty Acid Amide Hydrolase-2
Kaczocha, M., Glaser, S. T., Chae, J., Brown, D. A., & Deutsch, D. G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.058461 · Cited by 101
An acid amidase hydrolyzing anandamide as an endogenous ligand forcannabinoid receptors
Ueda, N., Yamanaka, K., Terasawa, Y., & Yamamoto, S. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00820-0 · Cited by 100
Monoacylglycerol lipase – a target for drug development?
Fowler, C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01950.x · Cited by 96
Cannabis and schizophrenia
Mcloughlin, B. C., Pushpa-Rajah, J. A., Gillies, D. M., Rathbone, J., Variend, H., Kalakouti, E., & Kyprianou, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004837.pub3 · Cited by 91
Cannabinoids in Experimental Stroke: A Systematic Review and Meta-Analysis
England, T. J., Hind, W. H., Rasid, N. A., & O’Sullivan, S. E. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.218 · Cited by 90
Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release
Hashimotodani, Y., Ohno‐Shosaku, T., Maejima, T., Fukami, K., & Kano, M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.002 · Cited by 90
Inhibition of fatty acid amide hydrolase produces PPAR‐α‐mediated analgesia in a rat model of inflammatory pain
Sagar, D. R., Kendall, D. A., & Chapman, V. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.335 · Cited by 89
The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2
Darmani, N. A. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01355-3 · Cited by 84
Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate
Rea, K., Roche, M., & Finn, D. P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707440 · Cited by 81
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis
Ball, S., Vickery, J., Hobart, J. C., Wright, D., Green, C., Shearer, J., Nunn, A., Cano, M. G., MacManus, D. G., Miller, D. H., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19120 · Cited by 78
The influence of cannabinoids on generic traits of neurodegeneration
Fagan, S. G., & Campbell, V. A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12492 · Cited by 78
Dynamic changes to the endocannabinoid system in models of chronic pain
Sagar, D. R., Burston, J. J., Woodhams, S. G., & Chapman, V. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0390 · Cited by 77
A S ativex®‐like combination of phytocannabinoids as a disease‐modifying therapy in a viral model of multiple sclerosis
Feliú, A., Moreno‐Martet, M., Mecha, M., Carrillo-Salinas, F. J., de Lago, E., Fernández‐Ruíz, J., & Guaza, C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13159 · Cited by 72
Endocannabinoid system and pain: an introduction
Burston, J. J., & Woodhams, S. G. (2013) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003650 · Cited by 67
Critical appraisal of the potential use of cannabinoids in cancer management
Rosengren, R. J., & Cridge, B. J. (2013) · Cancer Management and Research · doi:10.2147/cmar.s36105 · Cited by 66
Acute inhibition of diacylglycerol lipase blocks endocannabinoid‐mediated retrograde signalling: evidence for on‐demand biosynthesis of 2‐arachidonoylglycerol
Hashimotodani, Y., Ohno‐Shosaku, T., Tanimura, A., Kita, Y., Sano, Y., Shimizu, T., Marzo, V. D., & Kano, M. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.254474 · Cited by 62
Advances in the discovery of N-acylethanolamine acid amidase inhibitors
Bandiera, T., Ponzano, S., & Piomelli, D. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.04.011 · Cited by 60
Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat
Cross-Mellor, S. K., Ossenkopp, K., Piomelli, D., & Parker, L. A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0589-7 · Cited by 59
The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1
Fowler, C., Naidu, P., Lichtman, A. H., & Onnis, V. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00029.x · Cited by 57
Lack of effect of chronic pre‐treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system
Okine, B. N., Norris, L. M., Woodhams, S. G., Burston, J. J., Patel, A., Alexander, S. P. H., Barrett, D. A., Kendall, D. A., Bennett, A. J., & Chapman, V. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02028.x · Cited by 56
Self-citation
Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2‐arachidonoyl glycerol attenuates nausea in rats
Sticht, M. A., Long, J. Z., Rock, E. M., Limebeer, C. L., Mechoulam, R., Cravatt, B. F., & Parker, L. A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01407.x · Cited by 54
Classical endocannabinoid‐like compounds and their regulation by nutrients
Kleberg, K., Hassing, H. A., & Hansen, H. S. (2014) · BioFactors · doi:10.1002/biof.1158 · Cited by 51
The anti‐nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex
Limebeer, C. L., Rock, E., Mechoulam, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02066.x · Cited by 49
The multiple roles of fatty acid handling proteins in brain
Moullé, V. S. F., Cansell, C., Luquet, S., & Cruciani-Guglielmacci, C. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00385 · Cited by 49
GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119
Kang, S.-U. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.011 · Cited by 48
Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
Russo, M., Calabrò, R. S., Naro, A., Sessa, E., Rifici, C., D’Aleo, G., Leo, A., Luca, R. D., Quartarone, A., & Bramanti, P. (2015) · Neural Plasticity · doi:10.1155/2015/656582 · Cited by 48
[125I]SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer’s disease
Farkas, S., Nagy, K., Palkovits, M., Kovács, G. G., Jia, Z., Donohue, S. R., Pike, V. W., Halldin, C., Máthé, D., Harkany, T., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.11.004 · Cited by 47
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis
Hilliard, A., Stott, C. G., Wright, S., Guy, G. W., Pryce, G., Al‐Izki, S., Bolton, C., & Giovannoni, G. (2012) · ISRN Neurology · doi:10.5402/2012/802649 · Cited by 46
Critical appraisal of the potential use of cannabinoids in cancer management
Cridge, B. J., & Rosengren, R. J. (2013) · Dove Medical Press (Taylor and Francis Group) · Cited by 35
Cannabis and Schizophrenia
Pushpa-Rajah, J. A., Mcloughlin, B. C., Gillies, D. M., Rathbone, J., Variend, H., Kalakouti, E., & Kyprianou, K. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu168 · Cited by 28
A Biophysical Model of Endocannabinoid-Mediated Short Term Depression in Hippocampal Inhibition
Zachariou, M., Alexander, S. P. H., Coombes, S., & Christodoulou, C. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058926 · Cited by 24
Self-citation
The Synthetic Cannabinoid R(+)WIN55,212-2 Augments Interferon-β Expression via Peroxisome Proliferator-activated Receptor-α
Downer, E. J., Clifford, E., Amu, S., Fallon, P. G., & Moynagh, P. N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.371757 · Cited by 21
Untitled work
Khan (2000) · doi:10.1002/1531-8249(200008)48:2

Sorted by citations

Cannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
New approaches and challenges to targeting the endocannabinoid system
Marzo, V. D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 502
Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer
Pellati, F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S., & Corsi, L. (2018) · BioMed Research International · doi:10.1155/2018/1691428 · Cited by 430
“CBDA has antimicrobial and antinausea properties [1, 11, 13], while CBG has anti-inflammatory, antimicrobial, and analgesic activities [1, 11, 13, 15].”
Background
Cannabinoids and Cytochrome P450 Interactions
Zendulka, O., Dovrtělová, G., Nosková, K., Turjap, M., Šulcová, A., Hanuš, L., & Juřica, J. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666151210142051 · Cited by 308
“They are known to have a wide range of pharmacologic effects [7, 8], for which the hemp plant has been used for over 6000 years in herbal medicine and as a recreational drug.”
Background
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup‐Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 320

See all 151

Authors: Alexander, S. P. H.
Affiliations: University of Nottingham (GB)
Corresponding author: Alexander, Stephen P.H.
ORCID: Alexander, Stephen P.H.
Venue: Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher: Elsevier BV
Published: 2016-01
Volume: 64
Pages: 157-166
ISSN: 0278-5846 (ISSN-L)
DOI: 10.1016/j.pnpbp.2015.07.001
OpenAlex: W1580068968
Cited by: 149
References: 135
Citations by year: 2026: 4 · 2025: 6 · 2024: 12 · 2023: 24 · 2022: 13 · 2021: 15 · 2020: 10 · 2019: 28 · 2018: 14 · 2017: 14 · 2016: 6
FWCI: 1.59
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Complementary and alternative medicine › Nigella sativa pharmacological applications
Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Keywords: cannabis, cannabinoids, medical cannabis, pain, epilepsy, feeding disorders, multiple sclerosis, glaucoma, drug abuse, therapeutic potential
MeSH terms: Animals, Cannabinoids, Cannabis, Marijuana Abuse, Humans, Phytotherapy, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic potential of cannabis-related drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks